Jakob Lindberg

Biography

Jakob Lindberg was appointed as CEO in 2011. In addition to being CEO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, part of the Investor AB group of companies. Jakob’s previous roles include being an analyst for Merrill Lynch & Co and a consultant at McKinsey&Co. Jakob also co-founded Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO. Jakob studied medicine at the Karolinska Institute where he also gained a Med Lic in Molecular Immunology and an MSc in pre-clinical medicine. He also has a BA in Finance and Administration from Stockholm University. Born: 1972 Holdings in Oncopeptides: 235 409 shares (220,109 directly owned, 15,300 indirectly owned through Lindberg Life-Science AB) and 1,070 Share Options* Other current positions: Director of Affibody Medical AB, Alligator Bioscience AB, Atlas Antibodies AB, Dipylon Medical AB, Lindberg Life-Science AB and Bostadsrättsföreningen Astraea. Alternate Director of Oncopeptides Incentive AB. CEO of Lindberg Life-Science AB.

Research Interest

Jakob studied medicine at the Karolinska Institute where he also gained a Med Lic in Molecular Immunology and an MSc in pre-clinical medicine. He also has a BA in Finance and Administration from Stockholm University.